Orphan Drugs Partnering Terms & Agreements Disclosed in Comprehensive Report by CurrentPartnering

30 Apr 2013 • by Natalie Aster

A detailed understanding and analysis of how and why companies enter orphan drugs partnering deals are provided in the report “Orphan Drugs Partnering Terms and Agreements” by CurrentPartnering. The majority of deals entered are development stage whereby the licensee obtains a right or an option right to license the licensors product or technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest orphan drugs agreements announced in the healthcare sector.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

Report Details:

Orphan Drugs Partnering Terms and Agreements
Published: February, 2013
Pages: 227
Price: US$ 1,795.00

This report contains a comprehensive listing of all orphan drugs partnering deals announced since 2007 including financial terms where available including over 100 links to online deal records of actual orphan drugs partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of drug dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in orphan drugs dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading orphan drugs deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive and detailed review of orphan drugs partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy focus and specific technology type . Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in orphan drugs partnering and dealmaking since 2007.

In addition, a comprehensive appendix is provided organized by orphan drugs partnering company A-Z , deal type definitions and orphan drugs partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of orphan drugs technologies and products.

More information can be found in the report “Orphan Drugs Partnering Terms and Agreements” by CurrentPartnering.

To order the report or ask for sample pages contact [email protected]

Contacts

MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected]
MarketPublishers.com